Early DEtection of wEaring off in Parkinson disease: the DEEP study.

[1]  P. Barone,et al.  Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson’s disease , 2012, Neurological Sciences.

[2]  E. Růžička,et al.  Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? , 2012, Journal of Neural Transmission.

[3]  Angelo Antonini,et al.  Wearing‐off scales in Parkinson's disease: Critique and recommendations , 2011, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. Korczyn,et al.  Gender effect on time to levodopa-induced dyskinesias , 2011, Journal of Neurology.

[5]  Marios Politis,et al.  Parkinson's disease symptoms: The patient's perspective , 2010, Movement disorders : official journal of the Movement Disorder Society.

[6]  Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations. , 2010, Arquivos de neuro-psiquiatria.

[7]  M. Stacy.  The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease , 2010, Journal of Neural Transmission.

[8]  K. Sethi.  The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease , 2010, The neurologist.

[9]  K. Chaudhuri,et al.  Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson’s Disease , 2010, CNS drugs.

[10]  Kamran Nikbin,et al.  Validation of the K and J Parameters in a Compact Tension Specimen Containing Intergranular and Straight Crack Paths , 2010 .

[11]  A. Schapira,et al.  Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis , 2009, European journal of neurology.

[12]  V. Fung,et al.  Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone , 2009, Movement disorders : official journal of the Movement Disorder Society.

[13]  Utility of a patient survey in identifying fluctuations in early stage Parkinson’s disease , 2008, Journal of Clinical Neuroscience.

[14]  E. Tolosa,et al.  Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing‐off” in patients with Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. M. Stewart,et al.  The sensitivity and specificity of the 9-item Wearing-off Questionnaire. , 2008, Parkinsonism & related disorders.

[16]  Nobutaka Hattori,et al.  Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[17]  Stanley Fahn,et al.  Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.

[18]  Mark Stacy,et al.  Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment , 2005, Movement disorders : official journal of the Movement Disorder Society.

[19]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[20]  I. Katz,et al.  Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease , 2004, Journal of the American Geriatrics Society.

[21]  F. Stocchi.  Prevention and treatment of motor fluctuations. , 2003, Parkinsonism & related disorders.

[22]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[23]  C. Adler.  Relevance of motor complications in Parkinson’s disease , 2002, Neurology.

[24]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[25]  A Schrag,et al.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. , 2000, Brain : a journal of neurology.

[26]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[27]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[28]  R. Fitzpatrick,et al.  The PDQ-8: Development and validation of a short-form parkinson's disease questionnaire , 1997 .

[29]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[30]  C. Marsden,et al.  SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.

[31]  A. Prince,et al.  HEPANOSTICON IN SCREENING FOR HBsAg , 1975, The Lancet.